title: Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysis.
abstract: The aim of this retrospective study was to evaluate the toxicity profiles of dasatinib in patients with Philadelphia chromosome positive chronic myeloid leukemia (CML) or acute lymphatic leukemia (ALL) who were intolerant to imatinib, and who had been enrolled in our previous clinical trials to evaluate efficacy of dasatinib in patients resistant or tolerant to imatinib therapy. Twenty-four patients with CML and four with ALL were enrolled in the clinical studies to evaluate the efficacy according to the eligibility criteria related to intolerance to imatinib therapy. The toxicities reported during imatinib therapy were non-hematological toxicities in 23 patients and hematological toxicities in six patients. Patients were administered dasatinib 50-70 mg BID or 100 mg QD. Cross intolerance was observed in four patients who showed hematological toxicity after dasatinib treatment. However, it was possible to successfully continue therapy with only temporary interruption. No cross intolerance in non-hematological toxicity was found with the exception of one patient who showed cross intolerance, which did not result in treatment interruption. Dasatinib can be safely administered to imatinib-intolerant CML or Ph-positive ALL patients.
authors: Hematology Division, National Cancer Center Hospital, Tokyo, Japan. ykkobaya@ncc.go.jp.
authors: Yukio
authors: Y
authors: Kobayashi
authors: Hematology Division, Tokyo Metropolitan Cancer and Infectious diseases Center, Komagome Hospital, Tokyo, Japan.
authors: Hisashi
authors: H
authors: Sakamaki
authors: Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan.
authors: Shin
authors: S
authors: Fujisawa
authors: Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan.
authors: Kiyoshi
authors: K
authors: Ando
authors: Hematology and Cell Therapy Division, Aichi Cancer Center Hospital, Nagoya, Japan.
authors: Kazuhito
authors: K
authors: Yamamoto
authors: Division of Hematology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.
authors: Masaya
authors: M
authors: Okada
authors: Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai, Japan.
authors: Kenichi
authors: K
authors: Ishizawa
authors: Division of Hematology, Jichi Medical University, Shimotsuke, Japan.
authors: Tadashi
authors: T
authors: Nagai
authors: Leukemia Research Center, Saiseikai Maebashi Hospital, Maebashi, Japan.|Division of Hematology, Tokyo Metropolitan Ohtsuka Hospital, Tokyo, Japan.
authors: Syuichi
authors: S
authors: Miyawaki
authors: Department of Hematology, Tokyo Women's Medical University, Tokyo, Japan.
authors: Toshiko
authors: T
authors: Motoji
authors: Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.
authors: Noriko
authors: N
authors: Usui
authors: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
authors: Shinsuke
authors: S
authors: Iida
authors: Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
authors: Masafumi
authors: M
authors: Taniwaki
authors: Department of Internal Medicine, Matsushita Memorial Hospital, Osaka, Japan.
authors: Nobuhiko
authors: N
authors: Uoshima
authors: Bristol-Myers K.K, Tokyo, Japan.
authors: Taku
authors: T
authors: Seriu
authors: Aichi Cancer Center Hospital, Nagoya, Japan.
authors: Ryuzo
authors: R
authors: Ohno
references: N Engl J Med. 2006 Dec 7;355(23):2408-17
references: 17151364
references: Blood. 2007 Apr 15;109(8):3207-13
references: 17185463
references: Int J Hematol. 2009 Apr;89(3):332-341
references: 19263190
references: Int J Hematol. 2006 May;83(4):294-300
references: 16757427
references: N Engl J Med. 2010 Jun 17;362(24):2260-70
references: 20525995
references: Cancer Res. 2005 Jun 1;65(11):4500-5
references: 15930265
references: N Engl J Med. 2006 Jun 15;354(24):2542-51
references: 16775235
references: Blood. 2007 Mar 15;109(6):2303-9
references: 17138817
references: Blood. 2007 May 15;109(10):4143-50
references: 17264298
references: Clin Cancer Res. 2002 Jul;8(7):2167-76
references: 12114417
references: J Clin Oncol. 2008 Jul 1;26(19):3204-12
references: 18541900
references: Blood. 2007 Jun 15;109(12):5143-50
references: 17317857
references: N Engl J Med. 2001 Apr 5;344(14):1038-42
references: 11287973
references: Blood. 2009 May 28;113(22):5401-11
references: 19349618
references: Int J Hematol. 2009 Jun;89(5):664-72
references: 19455391
references: N Engl J Med. 2001 Apr 5;344(14):1031-7
references: 11287972
references: Blood. 2007 Oct 1;110(7):2309-15
references: 17496201